XNAS
IRON
Market cap2.33bUSD
Oct 08, Last price
60.77USD
1D
-0.67%
1Q
-20.66%
Name
IronPlanet Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
87.79%
Rev. gr., 5y
%
Revenues
0
Net income
-212m
L+94.03%
CFO
-180m
L+92.06%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Key people
James Jeffrey Jeter
President
Randall E. Berry
Senior Vice President - Operations and Services
Jeffrey L. Holmes
Senior Vice President - Government Solutions and Auction Management
Senior Vice President, Operations and Services
Jeffrey L. Barca-Hall
Senior Vice President - Engineering, Chief Technology Officer · since 2015
Susan T. Stillings
Chief Marketing Officer
Paul C. Blalock
Vice President of Sales
Matthew J. Bousky
Vice President - New Business Development
Douglas P. Feick
Senior Vice President, Corporate Development and Chief Legal Officer
Sue L. McGregor
Managing Director - Canada
Philip Kelliher
Director
Chairman of the Board, Chief Executive Officer · since 2015
Arthur C. Patterson
Director · since 2009
Mike Quirk
Director
Director · since 2010
Director · since 1999
Deborah M. Schleicher
Chief Financial Officer
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
3825 Hopyard Road
Suite 250
Pleasanton, CA 94588
US
Suite 250
Pleasanton, CA 94588
US
Previous name
IronPlanet.com, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||